Prevalence and factors associated with polypharmacy in older people with cancer
Tóm tắt
Polypharmacy has been associated with drug–drug interactions, adverse drug events, hospitalisation and increased mortality. The purpose of this study was to investigate the prevalence and factors associated with polypharmacy in older people with cancer. Patients aged ≥70 years (n = 385) presenting to the medical oncology outpatient clinic at Royal Adelaide Hospital between January 2009 and July 2010 completed a structured data collection instrument. The instrument included domains related to medications, diagnoses, instrumental activities of daily living (IADLs), Karnofsky Performance Scale (KPS), physical function (SF-36), pain (ten-point visual analogue scale, VAS), weight loss (patient self-reported over previous 6 months), exhaustion (CES-D) and distress (ten-point VAS). Frailty was computed using Fried’s frailty phenotype. Logistic regression was used to compute unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between polypharmacy (defined as five or more self-reported daily medications) and clinical parameters. Polypharmacy was present in 57 % (n = 221) of patients. When adjusting for age, gender and Charlson Comorbidity Index (CCI), polypharmacy was associated with being pre-frail (OR = 2.35, 95%CI = 1.43–3.86) and frail (OR = 4.48, 95%CI = 1.90–10.54) compared to being robust. When adjusting for age, gender, exhaustion, KPS, IADLs, pain and distress, polypharmacy was associated with higher CCI scores (OR = 1.58, 95%CI = 1.29–1.94) and poorer physical function (OR = 1.13, 95%CI = 1.06–1.20). Polypharmacy is highly prevalent in older people with cancer and associated with impaired physical function and being pre-frail and frail compared to being robust. Research is needed to identify strategies to minimize patients’ medication regimens.
Tài liệu tham khảo
Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB 3rd, Wildes T (2012) Senior adult oncology. J Natl Compr Canc Netw 10(2):162–209
Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4(5):419–428
Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104(9):1998–2005. doi:10.1002/cncr.21422
Merle L, Laroche ML, Dantoine T, Charmes JP (2005) Predicting and preventing adverse drug reactions in the very old. Drugs Aging 22(5):375–392
Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–237
Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz J-P, Lichtman S, Mor V, Monfardini S, Repetto L, Sørbye L, Topinkova E (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the Task Force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241–252. doi:10.1016/j.critrevonc.2005.06.003
Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65(9):989–995. doi:10.1016/j.jclinepi.2012.02.018
McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56(2):163–184. doi:10.1124/pr.56.2.4
Kaufman D, Kelly J, Rosenberg L, Anderson T, Mitchell A (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287(3):337–344
Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C (2012) Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol 3(3):228–237. doi:10.1016/j.jgo.2012.02.005
Flood KL, Carroll MB, Le CV, Brown CJ (2009) Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother 7(3):151–158. doi:10.1016/j.amjopharm.2009.05.002
Scott I, Jayathissa S (2010) Quality of drug prescribing in older patients: is there a problem and can we improve it? Intern Med J 40(1):7–18. doi:10.1111/j.1445-5994.2009.02040.x
Stegemann S, Ecker F, Maio M, Kraahs P, Wohlfart R, Breitkreutz J, Zimmer A, Bar-Shalom D, Hettrich P, Broegmann B (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Research Reviews 9(4):384–398. doi:10.1016/j.arr.2010.04.005
Roughead EE, Gilbert AL, Primrose JG, Sansom LN (1998) Drug-related hospital admissions: a review of Australian studies published 1988–1996. Med J Aust 168(8):405–408
Dalleur O, Spinewine A, Henrard S, Losseau C, Speybroeck N, Boland B (2012) Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START criteria. Drugs Aging 29(10):829–837. doi:10.1007/s40266-012-0016-1
Gaugler J, Duval S, Anderson K, Kane R (2007) Predicting nursing home admission in the U.S: a meta-analysis. BMC Geriatr 7(1):13
Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200–1205. doi:10.1001/jama.279.15.1200
Jorgensen T, Herrstedt J, Friis S, Hallas J (2012) Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol 3(1):33–40
Puts M, Costa-Lima B, Monette J, Girre V, Wolfson C, Baptist G, Bergman H (2009) Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 26(6):519–536
Tam-McDevitt J (2008) Polypharmacy, aging, and cancer. Oncology 22(9):1052–1055
Todd A, Williamson S, Husband A, Baqir W, Mahony M (2012) Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. doi:10.1007/s11096-012-9731-2
Riechelmann RP, Moreira F, Smaletz O, Saad ED (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290. doi:10.1007/s00280-004-0998-4
Lees J, Chan A (2011) Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 12(13):1249–1257. doi:10.1016/S1470-2045(11)70040-7
To T, Okera M, Prouse J, Prowse R, Singhal N (2010) Infancy of an Australian geriatric oncology program—characteristics of the first 200 patients. J Geriatr Oncol 1(2):81–86
Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC (1998) Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 82(10):1904–1908. doi:10.1002/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X
Fillenbaum GG, Smyer MA (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36(4):428–434
Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, p 196
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473–483
Orme JG, Reis J, Herz EJ (1986) Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) Scale. J Clin Psychol 42(1):28–33
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–156
Lees J, Toh B (2009) Does a pharmacist derived medication history (MH) provide more information than a geriatric cancer patient-completed medication list, and does it matter? Asia–Pac J Clin Oncol 5(Suppl 2):A176
Lau HS, Florax C, Porsius AJ, De Boer A (2001) The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 49(6):597–603
WHO Collaborating Centre for Drug Statistics Methodology (2011) Guidelines for ATC classification and DDD assignment, 2012
Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, McLachlan AJ, Abernethy DR, Banks E, Le Couteur DG (2012) High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 91(3):521–528. doi:10.1038/clpt.2011.258
Pal SK, Katheria V, Hurria A (2010) Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 60(2):120–132. doi:10.3322/caac.20059
Decoster L, Kenis C, Van Puyvelde K, Flamaing J, Conings G, De Greve J, Mets T, Milisen K, Lobelle JP, Wildiers H (2013) The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. J Geriatr Oncol 4(3):235–241. doi:10.1016/j.jgo.2013.04.010
Fusco O, Ferrini A, Santoro M, Lo Monaco MR, Gambassi G, Cesari M (2012) Physical function and perceived quality of life in older persons. Aging Clin Exp Res 24(1):68–73
Covinsky KE, Hilton J, Lindquist K, Dudley RA (2006) Development and validation of an index to predict activity of daily living dependence in community-dwelling elders. Med Care 44(2):149–157
Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, Zimmermann C, Del Giglio A, Riechelmann RP (2011) Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 19(9):1313–1318
Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR, Hilmer SN (2009) Drug burden index and physical function in older Australian men. Br J Clin Pharmacol 68(1):97–105. doi:10.1111/j.1365-2125.2009.03411.x
Kaplan GA, Strawbridge WJ, Camacho T, Cohen RD (1993) Factors associated with change in physical functioning in the elderly: a six-year prospective study. J Aging Health 5(1):140–153
Scott D, Blizzard L, Fell J, Jones G (2009) Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 102(9):625–633. doi:10.1093/qjmed/hcp093
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245
Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO (2014) Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. http://onlinelibrary.wiley.com/doi/10.1111/bcp.12292/abstract. Accessed 17 Jan 2014
Riechelmann RP, Krzyzanowska MK, Zimmermann C (2009) Futile medication use in terminally ill cancer patients. Support Care Cancer 17(6):745–748
Stavrou EP, Buckley N, Olivier J, Pearson SA (2012) Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open 2(3)
Balducci L, Goetz-Parten D, Steinman MA (2013) Polypharmacy and the management of the older cancer patient. Ann Oncol 24(suppl 7):vii36–40, 10.1093/annonc/mdt266
Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM (2007) Prescribing in palliative care as death approaches. J Am Geriatr Soc 55(4):590–595. doi:10.1111/j.1532-5415.2007.01124.x
Turner J, Singhal N, Bell JS (2013) Opportunities for deprescribing statins in patients with poor cancer prognosis. J Palliat Med. doi:10.1089/jpm.2013.0278
Frechen S, Zoeller A, Ruberg K, Voltz R, Gaertner J (2012) Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf 35(9):745–758
Cruz-Jentoft AJ, Boland B, Rexach L (2012) Drug therapy optimization at the end of life. Drugs Aging 29(6):511–521. doi:10.2165/11631740-000000000-00000